ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda struggles to deliver returns from massive Shire deal

With debt load reduced, drugmaker tasked with turning acquisitions into cash flow

Takeda President Christophe Weber has said the Shire deal was made with a decade down the road in mind. (Photo by Wataru Ito)

TOKYO -- Takeda Pharmaceutical's ambitious goal to increase sales to 5 trillion yen ($46 billion) in a decade was met with apathy from investors, underscoring the lack of returns from recent big-ticket acquisitions.

The Japanese drugmaker's stock has edged 2% lower since Dec. 9, when President and CEO Christophe Weber disclosed the sales goal to analysts, saying it can be achieved by fiscal 2030 -- the first concrete long-term target since the company's 2019 acquisition of Irish counterpart Shire for $62 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more